Sal Fuentes

I’m constantly asking myself, my teams and my colleagues: What second- and third-order effects of today’s innovations will become tomorrow’s biggest opportunities? As I write this, we are witnessing fascinating examples of strategic value creation unfold in real time. For instance, consider GLP-1 medications. By now, we’re all familiar with their impacts on healthcare. But…